OncoLab’s current main line of products, the Blood-based Biopsy Tests (BBB) enable the molecular detection of Circulating Tumor Cells (CTC) as a measure of therapy efficacy and recurrence of cancer. The presence, abundance and molecular characteristics of CTC are analyzed by immunofluorescence staining and automated image analysis and by quantification of RNA biomarkers specific for each type of cancer. A comprehensive, fast, most accurate, near-patient CTC detection, enumeration and molecular characterization system will be offered. A test for the detection and enumeration of Circulating Endothelial Cells (CEC) allows for investigating the damaging effect of several diseases on the vascular epithelium and its diagnostic impact. Another test detects Circulating Stromal Cells (CSC) which are indicative for endometrial diseases. CSC are a potential diagnostic target.
All Blood-based Biopsy Tests are non-invasive and rely on novel concepts ensuring unprecedented sensitivitiy and specificity. This has already been demonstrated for breast cancer and ovarian cancer. These tests will be provided for breast cancer, ovarian cancer, endometrial cancer, cervical cancer, colorectal cancer, and lung cancer.
Due to their non-invasive nature and easy applicability these blood tests represent so-called ‘LIQUID BIOPSIES’ which – unlike tissue biopsies – can theoretically be performed an unlimited number of times.
OncoLab Diagnostics GmbH
TFZ - Viktor Kaplan-Straße 2, Objekt E
2700 Wiener Neustadt